Background Preclinical studies and results of a phase 2 trial of abiraterone and olaparib
suggest a combined antitumor effect when the poly (adenosine diphosphate [ADP]-ribose) …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal
disease with current standard-of-care therapies. Homologous recombination repair (HRR) …

Background PROpel met its primary endpoint showing statistically significant improvement
in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus …

Background Patients with metastatic castration-resistant prostate cancer and homologous
recombination repair (HRR) mutations have a better response to treatment with the poly …

LBA16 Background: PROpel (NCT03732820) met its primary endpoint showing significant
investigator-assessed radiographic progression-free survival (rPFS) benefit for patients with …

Background Multiple loss-of-function alterations in genes that are involved in DNA repair,
including homologous recombination repair, are associated with response to poly …

11 Background: Preclinical studies have shown combined anti-tumor effect through
interactions between poly (adenosine diphosphate–ribose) polymerase and androgen …

PURPOSE Cediranib, a pan-vascular endothelial growth factor receptor inhibitor,
suppresses expression of homologous recombination repair (HRR) genes and increases …

Background We previously reported that olaparib led to significantly longer imaging-based
progression-free survival than the physician's choice of enzalutamide or abiraterone among …

BACKGROUND There are no validated clinical decision tools to aid optimal treatment
selection in men with metastatic castration‐resistant prostate cancer (mCRPC). Frequently …